Pharmaceutical companies are one of the biggest influences in the US economy and, subsequently, in United States law. It is clear that Big Pharma has lobbied against medical (and recreational) cannabis legalization as they stand to lose a substantial quantity of money.
States that have already legislated medical cannabis are already seeing the effects: prescription drug usage has decreased by an average of 11 percent. The National Academies of Science keeps track of the conditions most effectively treated with medical marijuana, and nearly all of them have high-profit prescription counterparts.
Among the conditions are glaucoma, chronic pain, nerve disorders/pain, post-traumatic stress disorder, anxiety, insomnia, and nausea/vomiting related to chemotherapy.
Big Pharma is a very powerful and lucrative industry. While $18.5 billion in losses over a 3 year period might appear massive, “medical cannabis would be a drop in the bucket when it comes to impacting the total pharmaceutical industry”, according to Giadha Aguirre De Carcer, creator and CEO of New Frontier Data.